Confronta i metodi
Esamina i metodi selezionati fianco a fianco; le righe che differiscono sono evidenziate.
| Scala di Valutazione della Demenza di Mattis× | Addenbrooke's Cognitive Examination× | |
|---|---|---|
| Campo | Neuropsicologia | Neuropsicologia |
| Famiglia | Process / pipeline | Process / pipeline |
| Anno di origine≠ | 1988 | 2000 |
| Ideatore≠ | Sandra Mattis | Padasalai Mathuranath |
| Tipo≠ | Clinician-administered comprehensive neuropsychological scale | Clinician-administered comprehensive cognitive examination |
| Fonte seminale≠ | Mattis, S. (1988). Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources. link ↗ | Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620. DOI ↗ |
| Alias≠ | DRS, Mattis DRS, Dementia Rating Scale | ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination |
| Correlati | 5 | 5 |
| Sintesi≠ | The Mattis Dementia Rating Scale (DRS) is a comprehensive 36-item clinician-administered neuropsychological battery designed to assess and quantify cognitive decline in dementia. Developed by Sandra Mattis in 1988, the DRS measures five major cognitive domains—attention, initiation/perseveration, construction, conceptualization, and memory—and provides both a total score and subscale scores. The DRS is particularly valued in neurodegenerative disease research and clinical settings for its sensitivity to cognitive change over time and its utility in detecting cognitive impairment across the dementia spectrum. | The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia. |
| ScholarGateInsieme di dati ↗ |
|
|